Abiomed (ABMD) Cash Flow Statement

Click line-items for a historical chart and %

Operating activities:
Net loss	21.79M
Adjustments required to reconcile net loss to net cash used for operating activities:
Depreciation and amortization
Bad debt expense	-13K
Stock-based compensation	18.05M
Write-down of inventory	1.35M
Loss on disposal of fixed assets
Deferred tax provision	9.78M
Gain on sale of WorldHeart common stock
Changes in assets and liabilities source (use):
Accounts receivable	-3.81M
Inventories	-6.28M
Prepaid expenses and other current assets	-2.03M
Accounts payable	1.91M
Accrued expenses
Deferred revenue	330K
Net cash used for operating activities
Investing activities:
Purchases of short-term marketable securities	-134.24M
Proceeds from the sale and maturity of short-term marketable securities	116.69M
Proceeds from the sale of WorldHeart common stock
Expenditures for property and equipment	-10.45M
Net cash (used in) provided by investing activities
Financing activities:
Proceeds from the exercise of stock options	5.76M
Net cash provided by financing activities
Effect of exchange rate changes on cash	272K
Net decrease in cash and cash equivalents	6.48M
Cash and cash equivalents at beginning of period	48.23M
Cash and cash equivalents at end of period	54.71M
Supplemental disclosure:
Fixed asset additions included in accounts payable	3.81M

Entities mentioned with ABMD